Report cover image

Anti-Obesity Prescription Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 124 Pages
SKU # APRC20543064

Description

Summary

According to APO Research, the global Anti-Obesity Prescription market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Anti-Obesity Prescription is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Anti-Obesity Prescription is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Anti-Obesity Prescription is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Anti-Obesity Prescription include Akrimax Pharmaceuticals, Alpex Pharma, Arena Pharmaceuticals, Arrowhead Research, Bridge BioResearch, Compellis Pharmaceuticals, Yungjin Pharm, Zealand Pharma and Zydus Cadila, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-Obesity Prescription, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Obesity Prescription.

The report will help the Anti-Obesity Prescription manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Anti-Obesity Prescription market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-Obesity Prescription market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Anti-Obesity Prescription Segment by Company

Akrimax Pharmaceuticals
Alpex Pharma
Arena Pharmaceuticals
Arrowhead Research
Bridge BioResearch
Compellis Pharmaceuticals
Yungjin Pharm
Zealand Pharma
Zydus Cadila
Anti-Obesity Prescription Segment by Type

Lorcaserin
Liraglutide
Phentermine and Topiramate
Orlistat
Bupropion and Naltrexone
Anti-Obesity Prescription Segment by Application

E-Commerce
Retail Pharmacies
Hospital Pharmacies
Anti-Obesity Prescription Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-Obesity Prescription manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-Obesity Prescription by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-Obesity Prescription in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

124 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Anti-Obesity Prescription Market Size (2020-2031)
2.2.2 Global Anti-Obesity Prescription Sales (2020-2031)
2.2.3 Global Anti-Obesity Prescription Market Average Price (2020-2031)
2.3 Anti-Obesity Prescription by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Lorcaserin
2.3.3 Liraglutide
2.3.4 Phentermine and Topiramate
2.3.5 Orlistat
2.3.6 Bupropion and Naltrexone
2.4 Anti-Obesity Prescription by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 E-Commerce
2.4.3 Retail Pharmacies
2.4.4 Hospital Pharmacies
3 Market Competitive Landscape by Manufacturers
3.1 Global Anti-Obesity Prescription Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Anti-Obesity Prescription Sales (k units) of Manufacturers (2020-2025)
3.3 Global Anti-Obesity Prescription Revenue of Manufacturers (2020-2025)
3.4 Global Anti-Obesity Prescription Average Price by Manufacturers (2020-2025)
3.5 Global Anti-Obesity Prescription Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Anti-Obesity Prescription, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Anti-Obesity Prescription, Product Type & Application
3.8 Global Manufacturers of Anti-Obesity Prescription, Established Date
3.9 Global Anti-Obesity Prescription Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Akrimax Pharmaceuticals
4.1.1 Akrimax Pharmaceuticals Company Information
4.1.2 Akrimax Pharmaceuticals Business Overview
4.1.3 Akrimax Pharmaceuticals Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio
4.1.5 Akrimax Pharmaceuticals Recent Developments
4.2 Alpex Pharma
4.2.1 Alpex Pharma Company Information
4.2.2 Alpex Pharma Business Overview
4.2.3 Alpex Pharma Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Alpex Pharma Anti-Obesity Prescription Product Portfolio
4.2.5 Alpex Pharma Recent Developments
4.3 Arena Pharmaceuticals
4.3.1 Arena Pharmaceuticals Company Information
4.3.2 Arena Pharmaceuticals Business Overview
4.3.3 Arena Pharmaceuticals Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio
4.3.5 Arena Pharmaceuticals Recent Developments
4.4 Arrowhead Research
4.4.1 Arrowhead Research Company Information
4.4.2 Arrowhead Research Business Overview
4.4.3 Arrowhead Research Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Arrowhead Research Anti-Obesity Prescription Product Portfolio
4.4.5 Arrowhead Research Recent Developments
4.5 Bridge BioResearch
4.5.1 Bridge BioResearch Company Information
4.5.2 Bridge BioResearch Business Overview
4.5.3 Bridge BioResearch Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Bridge BioResearch Anti-Obesity Prescription Product Portfolio
4.5.5 Bridge BioResearch Recent Developments
4.6 Compellis Pharmaceuticals
4.6.1 Compellis Pharmaceuticals Company Information
4.6.2 Compellis Pharmaceuticals Business Overview
4.6.3 Compellis Pharmaceuticals Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio
4.6.5 Compellis Pharmaceuticals Recent Developments
4.7 Yungjin Pharm
4.7.1 Yungjin Pharm Company Information
4.7.2 Yungjin Pharm Business Overview
4.7.3 Yungjin Pharm Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Yungjin Pharm Anti-Obesity Prescription Product Portfolio
4.7.5 Yungjin Pharm Recent Developments
4.8 Zealand Pharma
4.8.1 Zealand Pharma Company Information
4.8.2 Zealand Pharma Business Overview
4.8.3 Zealand Pharma Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Zealand Pharma Anti-Obesity Prescription Product Portfolio
4.8.5 Zealand Pharma Recent Developments
4.9 Zydus Cadila
4.9.1 Zydus Cadila Company Information
4.9.2 Zydus Cadila Business Overview
4.9.3 Zydus Cadila Anti-Obesity Prescription Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Zydus Cadila Anti-Obesity Prescription Product Portfolio
4.9.5 Zydus Cadila Recent Developments
5 Global Anti-Obesity Prescription Market Scenario by Region
5.1 Global Anti-Obesity Prescription Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Anti-Obesity Prescription Sales by Region: 2020-2031
5.2.1 Global Anti-Obesity Prescription Sales by Region: 2020-2025
5.2.2 Global Anti-Obesity Prescription Sales by Region: 2026-2031
5.3 Global Anti-Obesity Prescription Revenue by Region: 2020-2031
5.3.1 Global Anti-Obesity Prescription Revenue by Region: 2020-2025
5.3.2 Global Anti-Obesity Prescription Revenue by Region: 2026-2031
5.4 North America Anti-Obesity Prescription Market Facts & Figures by Country
5.4.1 North America Anti-Obesity Prescription Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Anti-Obesity Prescription Sales by Country (2020-2031)
5.4.3 North America Anti-Obesity Prescription Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Anti-Obesity Prescription Market Facts & Figures by Country
5.5.1 Europe Anti-Obesity Prescription Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Anti-Obesity Prescription Sales by Country (2020-2031)
5.5.3 Europe Anti-Obesity Prescription Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Anti-Obesity Prescription Market Facts & Figures by Country
5.6.1 Asia Pacific Anti-Obesity Prescription Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Anti-Obesity Prescription Sales by Country (2020-2031)
5.6.3 Asia Pacific Anti-Obesity Prescription Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Anti-Obesity Prescription Market Facts & Figures by Country
5.7.1 South America Anti-Obesity Prescription Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Anti-Obesity Prescription Sales by Country (2020-2031)
5.7.3 South America Anti-Obesity Prescription Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Anti-Obesity Prescription Market Facts & Figures by Country
5.8.1 Middle East and Africa Anti-Obesity Prescription Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Anti-Obesity Prescription Sales by Country (2020-2031)
5.8.3 Middle East and Africa Anti-Obesity Prescription Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Anti-Obesity Prescription Sales by Type (2020-2031)
6.1.1 Global Anti-Obesity Prescription Sales by Type (2020-2031) & (k units)
6.1.2 Global Anti-Obesity Prescription Sales Market Share by Type (2020-2031)
6.2 Global Anti-Obesity Prescription Revenue by Type (2020-2031)
6.2.1 Global Anti-Obesity Prescription Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Anti-Obesity Prescription Revenue Market Share by Type (2020-2031)
6.3 Global Anti-Obesity Prescription Price by Type (2020-2031)
7 Segment by Application
7.1 Global Anti-Obesity Prescription Sales by Application (2020-2031)
7.1.1 Global Anti-Obesity Prescription Sales by Application (2020-2031) & (k units)
7.1.2 Global Anti-Obesity Prescription Sales Market Share by Application (2020-2031)
7.2 Global Anti-Obesity Prescription Revenue by Application (2020-2031)
7.2.1 Global Anti-Obesity Prescription Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Anti-Obesity Prescription Revenue Market Share by Application (2020-2031)
7.3 Global Anti-Obesity Prescription Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Anti-Obesity Prescription Value Chain Analysis
8.1.1 Anti-Obesity Prescription Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Anti-Obesity Prescription Production Mode & Process
8.2 Anti-Obesity Prescription Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Anti-Obesity Prescription Distributors
8.2.3 Anti-Obesity Prescription Customers
9 Global Anti-Obesity Prescription Analyzing Market Dynamics
9.1 Anti-Obesity Prescription Industry Trends
9.2 Anti-Obesity Prescription Industry Drivers
9.3 Anti-Obesity Prescription Industry Opportunities and Challenges
9.4 Anti-Obesity Prescription Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Anti-Obesity Prescription Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
Table 6. Global Anti-Obesity Prescription Sales (k units) of Manufacturers (2020-2025)
Table 7. Global Anti-Obesity Prescription Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Anti-Obesity Prescription Revenue of Manufacturers (2020-2025)
Table 9. Global Anti-Obesity Prescription Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market Anti-Obesity Prescription Average Price (US$/unit) of Manufacturers (2020-2025)
Table 11. Global Anti-Obesity Prescription Industry Ranking, 2023 VS 2024 VS 2025
Table 12. Global Manufacturers of Anti-Obesity Prescription, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Anti-Obesity Prescription, Product Type & Application
Table 14. Global Anti-Obesity Prescription Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Anti-Obesity Prescription by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Akrimax Pharmaceuticals Company Information
Table 19. Akrimax Pharmaceuticals Business Overview
Table 20. Akrimax Pharmaceuticals Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 21. Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio
Table 22. Akrimax Pharmaceuticals Recent Developments
Table 23. Alpex Pharma Company Information
Table 24. Alpex Pharma Business Overview
Table 25. Alpex Pharma Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 26. Alpex Pharma Anti-Obesity Prescription Product Portfolio
Table 27. Alpex Pharma Recent Developments
Table 28. Arena Pharmaceuticals Company Information
Table 29. Arena Pharmaceuticals Business Overview
Table 30. Arena Pharmaceuticals Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 31. Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio
Table 32. Arena Pharmaceuticals Recent Developments
Table 33. Arrowhead Research Company Information
Table 34. Arrowhead Research Business Overview
Table 35. Arrowhead Research Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 36. Arrowhead Research Anti-Obesity Prescription Product Portfolio
Table 37. Arrowhead Research Recent Developments
Table 38. Bridge BioResearch Company Information
Table 39. Bridge BioResearch Business Overview
Table 40. Bridge BioResearch Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 41. Bridge BioResearch Anti-Obesity Prescription Product Portfolio
Table 42. Bridge BioResearch Recent Developments
Table 43. Compellis Pharmaceuticals Company Information
Table 44. Compellis Pharmaceuticals Business Overview
Table 45. Compellis Pharmaceuticals Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 46. Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio
Table 47. Compellis Pharmaceuticals Recent Developments
Table 48. Yungjin Pharm Company Information
Table 49. Yungjin Pharm Business Overview
Table 50. Yungjin Pharm Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 51. Yungjin Pharm Anti-Obesity Prescription Product Portfolio
Table 52. Yungjin Pharm Recent Developments
Table 53. Zealand Pharma Company Information
Table 54. Zealand Pharma Business Overview
Table 55. Zealand Pharma Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 56. Zealand Pharma Anti-Obesity Prescription Product Portfolio
Table 57. Zealand Pharma Recent Developments
Table 58. Zydus Cadila Company Information
Table 59. Zydus Cadila Business Overview
Table 60. Zydus Cadila Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 61. Zydus Cadila Anti-Obesity Prescription Product Portfolio
Table 62. Zydus Cadila Recent Developments
Table 63. Global Anti-Obesity Prescription Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 64. Global Anti-Obesity Prescription Sales by Region (2020-2025) & (k units)
Table 65. Global Anti-Obesity Prescription Sales Market Share by Region (2020-2025)
Table 66. Global Anti-Obesity Prescription Sales by Region (2026-2031) & (k units)
Table 67. Global Anti-Obesity Prescription Sales Market Share by Region (2026-2031)
Table 68. Global Anti-Obesity Prescription Revenue by Region (2020-2025) & (US$ Million)
Table 69. Global Anti-Obesity Prescription Revenue Market Share by Region (2020-2025)
Table 70. Global Anti-Obesity Prescription Revenue by Region (2026-2031) & (US$ Million)
Table 71. Global Anti-Obesity Prescription Revenue Market Share by Region (2026-2031)
Table 72. North America Anti-Obesity Prescription Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 73. North America Anti-Obesity Prescription Sales by Country (2020-2025) & (k units)
Table 74. North America Anti-Obesity Prescription Sales by Country (2026-2031) & (k units)
Table 75. North America Anti-Obesity Prescription Revenue by Country (2020-2025) & (US$ Million)
Table 76. North America Anti-Obesity Prescription Revenue by Country (2026-2031) & (US$ Million)
Table 77. Europe Anti-Obesity Prescription Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 78. Europe Anti-Obesity Prescription Sales by Country (2020-2025) & (k units)
Table 79. Europe Anti-Obesity Prescription Sales by Country (2026-2031) & (k units)
Table 80. Europe Anti-Obesity Prescription Revenue by Country (2020-2025) & (US$ Million)
Table 81. Europe Anti-Obesity Prescription Revenue by Country (2026-2031) & (US$ Million)
Table 82. Asia Pacific Anti-Obesity Prescription Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 83. Asia Pacific Anti-Obesity Prescription Sales by Country (2020-2025) & (k units)
Table 84. Asia Pacific Anti-Obesity Prescription Sales by Country (2026-2031) & (k units)
Table 85. Asia Pacific Anti-Obesity Prescription Revenue by Country (2020-2025) & (US$ Million)
Table 86. Asia Pacific Anti-Obesity Prescription Revenue by Country (2026-2031) & (US$ Million)
Table 87. South America Anti-Obesity Prescription Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 88. South America Anti-Obesity Prescription Sales by Country (2020-2025) & (k units)
Table 89. South America Anti-Obesity Prescription Sales by Country (2026-2031) & (k units)
Table 90. South America Anti-Obesity Prescription Revenue by Country (2020-2025) & (US$ Million)
Table 91. South America Anti-Obesity Prescription Revenue by Country (2026-2031) & (US$ Million)
Table 92. Middle East and Africa Anti-Obesity Prescription Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 93. Middle East and Africa Anti-Obesity Prescription Sales by Country (2020-2025) & (k units)
Table 94. Middle East and Africa Anti-Obesity Prescription Sales by Country (2026-2031) & (k units)
Table 95. Middle East and Africa Anti-Obesity Prescription Revenue by Country (2020-2025) & (US$ Million)
Table 96. Middle East and Africa Anti-Obesity Prescription Revenue by Country (2026-2031) & (US$ Million)
Table 97. Global Anti-Obesity Prescription Sales by Type (2020-2025) & (k units)
Table 98. Global Anti-Obesity Prescription Sales by Type (2026-2031) & (k units)
Table 99. Global Anti-Obesity Prescription Sales Market Share by Type (2020-2025)
Table 100. Global Anti-Obesity Prescription Sales Market Share by Type (2026-2031)
Table 101. Global Anti-Obesity Prescription Revenue by Type (2020-2025) & (US$ Million)
Table 102. Global Anti-Obesity Prescription Revenue by Type (2026-2031) & (US$ Million)
Table 103. Global Anti-Obesity Prescription Revenue Market Share by Type (2020-2025)
Table 104. Global Anti-Obesity Prescription Revenue Market Share by Type (2026-2031)
Table 105. Global Anti-Obesity Prescription Price by Type (2020-2025) & (US$/unit)
Table 106. Global Anti-Obesity Prescription Price by Type (2026-2031) & (US$/unit)
Table 107. Global Anti-Obesity Prescription Sales by Application (2020-2025) & (k units)
Table 108. Global Anti-Obesity Prescription Sales by Application (2026-2031) & (k units)
Table 109. Global Anti-Obesity Prescription Sales Market Share by Application (2020-2025)
Table 110. Global Anti-Obesity Prescription Sales Market Share by Application (2026-2031)
Table 111. Global Anti-Obesity Prescription Revenue by Application (2020-2025) & (US$ Million)
Table 112. Global Anti-Obesity Prescription Revenue by Application (2026-2031) & (US$ Million)
Table 113. Global Anti-Obesity Prescription Revenue Market Share by Application (2020-2025)
Table 114. Global Anti-Obesity Prescription Revenue Market Share by Application (2026-2031)
Table 115. Global Anti-Obesity Prescription Price by Application (2020-2025) & (US$/unit)
Table 116. Global Anti-Obesity Prescription Price by Application (2026-2031) & (US$/unit)
Table 117. Key Raw Materials
Table 118. Raw Materials Key Suppliers
Table 119. Anti-Obesity Prescription Distributors List
Table 120. Anti-Obesity Prescription Customers List
Table 121. Anti-Obesity Prescription Industry Trends
Table 122. Anti-Obesity Prescription Industry Drivers
Table 123. Anti-Obesity Prescription Industry Restraints
Table 124. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Anti-Obesity Prescription Product Image
Figure 5. Global Anti-Obesity Prescription Revenue (US$ Million), 2020 VS 2024 VS 2031
Figure 6. Global Anti-Obesity Prescription Market Size (2020-2031) & (US$ Million)
Figure 7. Global Anti-Obesity Prescription Sales (2020-2031) & (k units)
Figure 8. Global Anti-Obesity Prescription Average Price (US$/unit) & (2020-2031)
Figure 9. Lorcaserin Product Image
Figure 10. Liraglutide Product Image
Figure 11. Phentermine and Topiramate Product Image
Figure 12. Orlistat Product Image
Figure 13. Bupropion and Naltrexone Product Image
Figure 14. E-Commerce Product Image
Figure 15. Retail Pharmacies Product Image
Figure 16. Hospital Pharmacies Product Image
Figure 17. Global Anti-Obesity Prescription Revenue Share by Manufacturers in 2024
Figure 18. Global Manufacturers of Anti-Obesity Prescription, Manufacturing Sites & Headquarters
Figure 19. Global Top 5 and 10 Anti-Obesity Prescription Players Market Share by Revenue in 2024
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Anti-Obesity Prescription Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. Global Anti-Obesity Prescription Sales by Region in 2024
Figure 23. Global Anti-Obesity Prescription Revenue by Region in 2024
Figure 24. North America Anti-Obesity Prescription Market Size by Country in 2024
Figure 25. North America Anti-Obesity Prescription Sales Market Share by Country (2020-2031)
Figure 26. North America Anti-Obesity Prescription Revenue Market Share by Country (2020-2031)
Figure 27. United States Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe Anti-Obesity Prescription Market Size by Country in 2024
Figure 30. Europe Anti-Obesity Prescription Sales Market Share by Country (2020-2031)
Figure 31. Europe Anti-Obesity Prescription Revenue Market Share by Country (2020-2031)
Figure 32. Germany Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Netherlands Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Nordic Countries Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Asia Pacific Anti-Obesity Prescription Market Size by Country in 2024
Figure 39. Asia Pacific Anti-Obesity Prescription Sales Market Share by Country (2020-2031)
Figure 40. Asia Pacific Anti-Obesity Prescription Revenue Market Share by Country (2020-2031)
Figure 41. China Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Japan Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. South Korea Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. India Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Australia Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. China Taiwan Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Southeast Asia Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Southeast Asia Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. South America Anti-Obesity Prescription Market Size by Country in 2024
Figure 50. South America Anti-Obesity Prescription Sales Market Share by Country (2020-2031)
Figure 51. South America Anti-Obesity Prescription Revenue Market Share by Country (2020-2031)
Figure 52. Mexico Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Brazil Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Argentina Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Middle East and Africa Anti-Obesity Prescription Market Size by Country in 2024
Figure 56. Middle East and Africa Anti-Obesity Prescription Sales Market Share by Country (2020-2031)
Figure 57. Middle East and Africa Anti-Obesity Prescription Revenue Market Share by Country (2020-2031)
Figure 58. Turkey Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. Saudi Arabia Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 60. UAE Anti-Obesity Prescription Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 61. Global Anti-Obesity Prescription Sales Market Share by Type (2020-2031)
Figure 62. Global Anti-Obesity Prescription Revenue Market Share by Type (2020-2031)
Figure 63. Global Anti-Obesity Prescription Price (US$/unit) by Type (2020-2031)
Figure 64. Global Anti-Obesity Prescription Sales Market Share by Application (2020-2031)
Figure 65. Global Anti-Obesity Prescription Revenue Market Share by Application (2020-2031)
Figure 66. Global Anti-Obesity Prescription Price (US$/unit) by Application (2020-2031)
Figure 67. Anti-Obesity Prescription Value Chain
Figure 68. Anti-Obesity Prescription Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Anti-Obesity Prescription Industry Opportunities and Challenges
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.